CheckMate 649 Long-term Follow-up: Nivolumab Plus Chemotherapy for Gastric Esophageal Cancers
By Yelena Janjigian, MD - Last Updated: March 19, 2025Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, details the extended follow-up results of CheckMate 649, which examined the efficacy of nivolumab with chemotherapy for the treatment of advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Advertisement
Dr. Janjigian describes how the study’s initial results compared to its 3-year follow-up results, along with the history of nivolumab treatment for advanced disease.
Advertisement
Related Posts
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.